Douglas Blankenship
Plus aucun poste en cours
Fortune : 504 $ au 31/05/2024
Profil
Douglas L.
Blankenship is currently the Chief Financial Officer at Holdco Nuvo.
Group DG Ltd.
He previously worked as the Director-Global Quality, Compliance & Technical at Genentech, Inc. from 2006 to 2015, Director-Global Quality & Compliance at Roche Pharmaceuticals, Inc. from 2008 to 2015, Finance Director at Amgen Technology (Ireland) Unlimited Co. from 2006 to 2008, and CFO & Principal Accounting Officer at Dova Pharmaceuticals, Inc. from 2017 to 2018.
Mr. Blankenship obtained an undergraduate degree from California Polytechnic State University (San Luis Obispo) and an MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,00% | 01/05/2024 | 385 ( 0,00% ) | 504 $ | 31/05/2024 |
Postes actifs de Douglas Blankenship
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Douglas Blankenship
| Sociétés | Poste | Fin |
|---|---|---|
Humacyte Global, Inc.
 Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Directeur Financier/CFO | 19/05/2021 |
| DOVA PHARMACEUTICALS, INC. | Directeur Financier/CFO | 31/01/2018 |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Compliance Officer | 01/10/2015 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/10/2015 |
Amgen Technology (Ireland) Unlimited Co.
 Amgen Technology (Ireland) Unlimited Co. Medical/Nursing ServicesHealth Services Part of Amgen, Inc., Amgen Technology (Ireland) Unlimited Co. is an Irish company committed to unlocking the potential of biology for patients suffering from serious illnesses. The company is based in Dublin, Ireland and is dedicated to serving patients by finding new solutions that improve lives through the potential of biology. With a robust pipeline and state-of-the-art science and molecular engineering, Amgen Technology (Ireland aims to create transformative medicines with large effects in serious diseases. The company, founded in 2006, focuses on developing and delivering transformative medicines to meet the needs of patients. | Directeur Financier/CFO | 01/01/2008 |
Formation de Douglas Blankenship
| California Polytechnic State University (San Luis Obispo) | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Commercial Services |
Humacyte Global, Inc.
Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Health Technology |
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
Amgen Technology (Ireland) Unlimited Co.
Amgen Technology (Ireland) Unlimited Co. Medical/Nursing ServicesHealth Services Part of Amgen, Inc., Amgen Technology (Ireland) Unlimited Co. is an Irish company committed to unlocking the potential of biology for patients suffering from serious illnesses. The company is based in Dublin, Ireland and is dedicated to serving patients by finding new solutions that improve lives through the potential of biology. With a robust pipeline and state-of-the-art science and molecular engineering, Amgen Technology (Ireland aims to create transformative medicines with large effects in serious diseases. The company, founded in 2006, focuses on developing and delivering transformative medicines to meet the needs of patients. | Health Services |
